The Burden of Human Metapneumovirus (hMPV) Disease in Older and High-Risk Adults in Developed Countries: A Systematic Literature Review
Abstract Introduction Human metapneumovirus (hMPV) causes respiratory infections in individuals of all age groups. While the evidence on hMPV epidemiology is growing, the hMPV burden in adults has not been synthesised. We conducted a critical review of published evidence on the burden of hMPV in old...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-07-01
|
| Series: | Infectious Diseases and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40121-025-01187-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849763934520737792 |
|---|---|
| author | Ajoke Sobanjo-ter Meulen Aura V. Gutierrez Ornella Ruiz Jennifer Eeuwijk Hilde Vroling Niranjan Kanesa-thasan |
| author_facet | Ajoke Sobanjo-ter Meulen Aura V. Gutierrez Ornella Ruiz Jennifer Eeuwijk Hilde Vroling Niranjan Kanesa-thasan |
| author_sort | Ajoke Sobanjo-ter Meulen |
| collection | DOAJ |
| description | Abstract Introduction Human metapneumovirus (hMPV) causes respiratory infections in individuals of all age groups. While the evidence on hMPV epidemiology is growing, the hMPV burden in adults has not been synthesised. We conducted a critical review of published evidence on the burden of hMPV in older adults and adults with comorbidities. Methods Articles reporting the burden of hMPV disease in adults ⩾50 years or ⩾18 years with comorbidities in developed countries were searched in Embase and MEDLINE (1/January/2000–12/June/2023) databases. Observational and interventional studies on community-based or medically attended populations were included. Outcomes of interest encompassed prevalence, incidence, clinical presentation, severe outcomes and complications, healthcare utilisation, coinfection with respiratory syncytial virus or influenza, and child-to-adult transmission. We assessed the risk of bias, performed a qualitative and quantitative synthesis, and calculated pooled estimates using random-effects meta-analysis (PROSPERO: CRD42023439068). Results In total, 119 of 2847 articles met the inclusion criteria, covering 663,361 patients. hMPV accounted for 3.4% (95% confidence interval [CI] 2.7–4.2%, I 2 = 66%) of annual and 4.0% (95% CI 2.9–5.3%, I 2 = 78%) of seasonal symptomatic respiratory infections in older adults and 4.3% (95% CI 3.2–5.7%, I 2 = 66%, annual) and 5.1% (95% CI 3.2–7.9%, I 2 = 82%, seasonal) in high-risk adults. For high-risk adults, the estimated proportion of hMPV cases requiring hospitalisation was 51.4% (95% CI 33.2–69.3%, I 2 = 46%). Among medically attended cases, the proportions admitted to the intensive care unit and those resulting in mortality were 6.6% (95% CI 4.8–9.1%, I 2 = 34%) and 9.3% (95% CI 4.6–18%, I 2 = 0%), respectively. Conclusions hMPV burden is substantial in the adult population, particularly among those with underlying diseases. Limited evidence exists in community settings, alongside the lack of routine testing for hMPV, which hinders the estimation of the actual burden of hMPV. These findings underscore the need for tailored prevention and treatment strategies for hMPV infection, such as vaccination or antiviral treatments. |
| format | Article |
| id | doaj-art-fa3689049c694f0ba8d13f005b3e788f |
| institution | DOAJ |
| issn | 2193-8229 2193-6382 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Infectious Diseases and Therapy |
| spelling | doaj-art-fa3689049c694f0ba8d13f005b3e788f2025-08-20T03:05:16ZengAdis, Springer HealthcareInfectious Diseases and Therapy2193-82292193-63822025-07-011481917193310.1007/s40121-025-01187-2The Burden of Human Metapneumovirus (hMPV) Disease in Older and High-Risk Adults in Developed Countries: A Systematic Literature ReviewAjoke Sobanjo-ter Meulen0Aura V. Gutierrez1Ornella Ruiz2Jennifer Eeuwijk3Hilde Vroling4Niranjan Kanesa-thasan5Icosavax, Vaccines and Immune Therapies, BioPharmaceuticals Medical, AstraZenecaP95 Clinical & Epidemiology ServicesP95 Clinical & Epidemiology ServicesP95 Clinical & Epidemiology ServicesP95 Clinical & Epidemiology ServicesIcosavax, Vaccines and Immune Therapies, BioPharmaceuticals Medical, AstraZenecaAbstract Introduction Human metapneumovirus (hMPV) causes respiratory infections in individuals of all age groups. While the evidence on hMPV epidemiology is growing, the hMPV burden in adults has not been synthesised. We conducted a critical review of published evidence on the burden of hMPV in older adults and adults with comorbidities. Methods Articles reporting the burden of hMPV disease in adults ⩾50 years or ⩾18 years with comorbidities in developed countries were searched in Embase and MEDLINE (1/January/2000–12/June/2023) databases. Observational and interventional studies on community-based or medically attended populations were included. Outcomes of interest encompassed prevalence, incidence, clinical presentation, severe outcomes and complications, healthcare utilisation, coinfection with respiratory syncytial virus or influenza, and child-to-adult transmission. We assessed the risk of bias, performed a qualitative and quantitative synthesis, and calculated pooled estimates using random-effects meta-analysis (PROSPERO: CRD42023439068). Results In total, 119 of 2847 articles met the inclusion criteria, covering 663,361 patients. hMPV accounted for 3.4% (95% confidence interval [CI] 2.7–4.2%, I 2 = 66%) of annual and 4.0% (95% CI 2.9–5.3%, I 2 = 78%) of seasonal symptomatic respiratory infections in older adults and 4.3% (95% CI 3.2–5.7%, I 2 = 66%, annual) and 5.1% (95% CI 3.2–7.9%, I 2 = 82%, seasonal) in high-risk adults. For high-risk adults, the estimated proportion of hMPV cases requiring hospitalisation was 51.4% (95% CI 33.2–69.3%, I 2 = 46%). Among medically attended cases, the proportions admitted to the intensive care unit and those resulting in mortality were 6.6% (95% CI 4.8–9.1%, I 2 = 34%) and 9.3% (95% CI 4.6–18%, I 2 = 0%), respectively. Conclusions hMPV burden is substantial in the adult population, particularly among those with underlying diseases. Limited evidence exists in community settings, alongside the lack of routine testing for hMPV, which hinders the estimation of the actual burden of hMPV. These findings underscore the need for tailored prevention and treatment strategies for hMPV infection, such as vaccination or antiviral treatments.https://doi.org/10.1007/s40121-025-01187-2Burden of diseaseEpidemiologyHigh-risk groupsHuman metapneumovirusRespiratory virusRespiratory virus infection |
| spellingShingle | Ajoke Sobanjo-ter Meulen Aura V. Gutierrez Ornella Ruiz Jennifer Eeuwijk Hilde Vroling Niranjan Kanesa-thasan The Burden of Human Metapneumovirus (hMPV) Disease in Older and High-Risk Adults in Developed Countries: A Systematic Literature Review Infectious Diseases and Therapy Burden of disease Epidemiology High-risk groups Human metapneumovirus Respiratory virus Respiratory virus infection |
| title | The Burden of Human Metapneumovirus (hMPV) Disease in Older and High-Risk Adults in Developed Countries: A Systematic Literature Review |
| title_full | The Burden of Human Metapneumovirus (hMPV) Disease in Older and High-Risk Adults in Developed Countries: A Systematic Literature Review |
| title_fullStr | The Burden of Human Metapneumovirus (hMPV) Disease in Older and High-Risk Adults in Developed Countries: A Systematic Literature Review |
| title_full_unstemmed | The Burden of Human Metapneumovirus (hMPV) Disease in Older and High-Risk Adults in Developed Countries: A Systematic Literature Review |
| title_short | The Burden of Human Metapneumovirus (hMPV) Disease in Older and High-Risk Adults in Developed Countries: A Systematic Literature Review |
| title_sort | burden of human metapneumovirus hmpv disease in older and high risk adults in developed countries a systematic literature review |
| topic | Burden of disease Epidemiology High-risk groups Human metapneumovirus Respiratory virus Respiratory virus infection |
| url | https://doi.org/10.1007/s40121-025-01187-2 |
| work_keys_str_mv | AT ajokesobanjotermeulen theburdenofhumanmetapneumovirushmpvdiseaseinolderandhighriskadultsindevelopedcountriesasystematicliteraturereview AT auravgutierrez theburdenofhumanmetapneumovirushmpvdiseaseinolderandhighriskadultsindevelopedcountriesasystematicliteraturereview AT ornellaruiz theburdenofhumanmetapneumovirushmpvdiseaseinolderandhighriskadultsindevelopedcountriesasystematicliteraturereview AT jennifereeuwijk theburdenofhumanmetapneumovirushmpvdiseaseinolderandhighriskadultsindevelopedcountriesasystematicliteraturereview AT hildevroling theburdenofhumanmetapneumovirushmpvdiseaseinolderandhighriskadultsindevelopedcountriesasystematicliteraturereview AT niranjankanesathasan theburdenofhumanmetapneumovirushmpvdiseaseinolderandhighriskadultsindevelopedcountriesasystematicliteraturereview AT ajokesobanjotermeulen burdenofhumanmetapneumovirushmpvdiseaseinolderandhighriskadultsindevelopedcountriesasystematicliteraturereview AT auravgutierrez burdenofhumanmetapneumovirushmpvdiseaseinolderandhighriskadultsindevelopedcountriesasystematicliteraturereview AT ornellaruiz burdenofhumanmetapneumovirushmpvdiseaseinolderandhighriskadultsindevelopedcountriesasystematicliteraturereview AT jennifereeuwijk burdenofhumanmetapneumovirushmpvdiseaseinolderandhighriskadultsindevelopedcountriesasystematicliteraturereview AT hildevroling burdenofhumanmetapneumovirushmpvdiseaseinolderandhighriskadultsindevelopedcountriesasystematicliteraturereview AT niranjankanesathasan burdenofhumanmetapneumovirushmpvdiseaseinolderandhighriskadultsindevelopedcountriesasystematicliteraturereview |